Mayinglong Pharmaceutical Group's MYL Ointment Gets Regulatory Approval for Clinical Trials

MT Newswires Live12-10

Mayinglong Pharmaceutical Group (SHA:600993) received a Drug Clinical Trial Approval Notice for MYL Ointment from China's National Medical Products Administration (NMPA), according to a Saturday filing with the Shanghai bourse.

Provisionally named Tiger Musk Hemostatic and Analgesic Ointment, it is meant to treat hemorrhoidal symptoms and post-surgical complications.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment